- Acurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Global 2026
May 4, 2026 · prnewswire.com
DNA pol IIIC inhibitors demonstrate the unexpected benefit of gut microbiome preservation while demonstrating systemic antibacterial activity Neutropenic CD-1 mice were infected intramuscularly with methicillin-resistant Staphylococcus aureus (MRSA) and subsequently treated with one of three Acurx DNA pol IIIC inhibitors, linezolid, or placebo administered orally Acurx compounds achieved potentially therapeutic plasma levels and reduced MRSA tissue burden Acurx antibiotics maintained a substantially higher gut microbial diversity and a community structure similar to baseline and distinct from linezolid Unlike linezolid, ACX compounds maintain Bacteroidota-dominant community structure and prevent Proteobacteria expansion in the gastrointestinal tract DNA pol IIIC inhibitors demonstrate a class effect of potentially clinically-relevant gut microbiome preservation while demonstrating systemic antibacterial activity Acurx's DNA pol IIIC inhibitor preclinical product candidates are FDA QIDP and Fast-Track eligible and target Gram-positive infections classified as Serious Threat priorities by CDC STATEN ISLAND, N.Y., May 4, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced presentation of a scientific poster at the 35th Congress of ESCMID Global (European Society of Clinical Microbiology and Infectious Diseases) held in Munich, Germany from April 17-21, 2026.
- ACURX ANNOUNCES SCIENTIFIC POSTER PRESENTATION OF ITS DNA POL IIIC INHIBITORS' MICROBIOME EVALUATION AT ESCMID GLOBAL 2026
May 4, 2026
DNA POL IIIC INHIBITORS DEMONSTRATE THE UNEXPECTED BENEFIT OF GUT MICROBIOME PRESERVATION WHILE DEMONSTRATING SYSTEMIC ANTIBACTERIAL ACTIVITY NEUTROPENIC CD-1 MICE WERE INFECTED INTRAMUSCULARLY WITH METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) AND SUBSEQUENTLY TREATED WITH ONE OF THREE ACURX DNA POL IIIC INHIBITORS, LINEZOLID, OR PLACEBO ADMINISTERED ORALLY ACURX COMPOUNDS ACHIEVED POTENTIALLY THERAPEUTIC PLASMA LEVELS AND REDUCED MRSA TISSUE BURDEN ACURX ANTIBIOTICS MAINTAINED A SUBSTANTIALLY HIGHER GUT MICROBIAL DIVERSITY AND A COMMUNITY STRUCTURE SIMILAR TO BASELINE AND DISTINCT FROM LINEZOLID UNLIKE LINEZOLID, ACX COMPOUNDS MAINTAIN BACTEROIDOTA-DOMINANT COMMUNITY STRUCTURE AND PREVENT PROTEOBACTERIA EXPANSION IN THE GASTROINTESTINAL TRACT DNA POL IIIC INHIBITORS DEMONSTRATE A CLASS EFFECT OF POTENTIALLY CLINICALLY-RELEVANT GUT MICROBIOME PRESERVATION WHILE DEMONSTRATING SYSTEMIC ANTIBACTERIAL ACTIVITY ACURX'S DNA POL IIIC INHIBITOR PRECLINICAL PRODUCT CANDIDATES ARE FDA QIDP AND FAST-TRACK ELIGIBLE AND TARGET GRAM-POSITIVE INFECTIONS CLASSIFIED AS SERIOUS THREAT PRIORITIES BY CDC STATEN ISLAND, N.Y., MAY 4, 2026 /PRNEWSWIRE/ -- ACURX PHARMACEUTICALS, INC. (NASDAQ: ACXP) ("ACURX" OR THE "COMPANY"), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING A NEW CLASS OF ANTIBIOTICS FOR DIFFICULT-TO-TREAT BACTERIAL INFECTIONS, TODAY ANNOUNCED PRESENTATION OF A SCIENTIFIC POSTER AT THE 35TH CONGRESS OF ESCMID GLOBAL (EUROPEAN SOCIETY OF CLINICAL MICROBIOLOGY AND INFECTIOUS DISEASES) HELD IN MUNICH, GERMANY FROM APRIL 17-21, 2026.
- Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase
Apr 29, 2026 · prnewswire.com
STATEN ISLAND, N.Y., April 29, 2026 /PRNewswire/ -- Acurx Pharmaceuticals (Nasdaq: ACXP) (Acurx or the Company), a fully-integrated biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections announced today that David P.
- ACURX PHARMACEUTICALS TO PRESENT AT THE ALLIANCE GLOBAL PARTNERS (A.G.P) HEALTHCARE COMPANY SHOWCASE
Apr 29, 2026
STATEN ISLAND, N.Y., APRIL 29, 2026 /PRNEWSWIRE/ -- ACURX PHARMACEUTICALS (NASDAQ: ACXP) (ACURX OR THE COMPANY), A FULLY-INTEGRATED BIOPHARMACEUTICAL COMPANY DEVELOPING A NEW CLASS OF ANTIBIOTICS FOR DIFFICULT-TO-TREAT BACTERIAL INFECTIONS ANNOUNCED TODAY THAT DAVID P.
- Acurx Pharmaceuticals, Inc. To Present at The Market Movers Investor Summit
Apr 27, 2026 · newsfilecorp.com
Staten Island, New York--(Newsfile Corp. - April 27, 2026) - Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced that it will be participating in the Market Movers Investor Summit on Tuesday May 5, 2026. The presentation will take place at 05:20 PM ET at the historic Bank of New York.
- ACURX PHARMACEUTICALS, INC. TO PRESENT AT THE MARKET MOVERS INVESTOR SUMMIT
Apr 27, 2026
STATEN ISLAND, NEW YORK--(NEWSFILE CORP. - APRIL 27, 2026) - ACURX PHARMACEUTICALS, INC. (NASDAQ: ACXP) ("WE" OR "ACURX" OR THE "COMPANY"), A LATE-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING A NEW CLASS OF ANTIBIOTICS FOR DIFFICULT-TO-TREAT BACTERIAL INFECTIONS, TODAY ANNOUNCED THAT IT WILL BE PARTICIPATING IN THE MARKET MOVERS INVESTOR SUMMIT ON TUESDAY MAY 5, 2026. THE PRESENTATION WILL TAKE PLACE AT 05:20 PM ET AT THE HISTORIC BANK OF NEW YORK.
- Acurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 12, 2026 Conference Call and Provide Business Update
Apr 20, 2026 · prnewswire.com
STATEN ISLAND, N.Y., April 20, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its first quarter 2026 financial results on Tuesday, May 12, 2026 at 8:00 am ET before the U.S. financial markets open.
- ACURX PHARMACEUTICALS TO DISCUSS FIRST QUARTER 2026 FINANCIAL RESULTS ON MAY 12, 2026 CONFERENCE CALL AND PROVIDE BUSINESS UPDATE
Apr 20, 2026
STATEN ISLAND, N.Y., APRIL 20, 2026 /PRNEWSWIRE/ -- ACURX PHARMACEUTICALS, INC. (NASDAQ: ACXP) ("ACURX" OR THE "COMPANY"), A LATE-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING A NEW CLASS OF ANTIBIOTICS FOR DIFFICULT-TO-TREAT BACTERIAL INFECTIONS, ANNOUNCED TODAY THAT THE COMPANY WILL DISCUSS ITS FIRST QUARTER 2026 FINANCIAL RESULTS ON TUESDAY, MAY 12, 2026 AT 8:00 AM ET BEFORE THE U.S. FINANCIAL MARKETS OPEN.
- Acurx Pharmaceuticals, Inc. Announces Closing of up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Apr 16, 2026 · prnewswire.com
$2.5 million upfront with up to an additional $4.6 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants STATEN ISLAND, N.Y., April 16, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced the closing of its previously announced registered direct offering of 825,085 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price of $3.03 per share (or pre-funded warrant in lieu thereof) priced at-the-market under Nasdaq rules.
- ACURX PHARMACEUTICALS, INC. ANNOUNCES CLOSING OF UP TO $7.1 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES
Apr 16, 2026
$2.5 MILLION UPFRONT WITH UP TO AN ADDITIONAL $4.6 MILLION OF POTENTIAL AGGREGATE GROSS PROCEEDS UPON THE EXERCISE IN FULL OF SHORT-TERM WARRANTS STATEN ISLAND, N.Y., APRIL 16, 2026 /PRNEWSWIRE/ -- ACURX PHARMACEUTICALS, INC. (NASDAQ: ACXP) ("WE" OR "ACURX" OR THE "COMPANY"), A LATE-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING A NEW CLASS OF ANTIBIOTICS FOR DIFFICULT-TO-TREAT BACTERIAL INFECTIONS, TODAY ANNOUNCED THE CLOSING OF ITS PREVIOUSLY ANNOUNCED REGISTERED DIRECT OFFERING OF 825,085 SHARES OF ITS COMMON STOCK (OR PRE-FUNDED WARRANTS IN LIEU THEREOF) AT A PURCHASE PRICE OF $3.03 PER SHARE (OR PRE-FUNDED WARRANT IN LIEU THEREOF) PRICED AT-THE-MARKET UNDER NASDAQ RULES.
